Abstract: Leucovorin-modulated 5-fluorouracil (5-FU) plus irinotecan (FOLFIRI) is the most common treatment of metastatic colorectal cancer (CRC). 5-FU inhibits thymidylate synthase (TS) and irinotecan topoisomerase I, leading to inhibition of DNA replication and repair. FOLFIRI efficacy suggested that other TS inhibitors might synergize with irinotecan, and Phase I/II studies for second-line treatment showed promising results of combinations with the multitargeted antifolate pemetrexed (PMX), which exerts its effects primarily via TS inhibition. However, a randomized Phase II trial of PMX + irinotecan (ALIRI) showed similar efficacy and safety, but significantly shorter progression-free survival (PFS) compared with FOLFIRI in locally advanced or metastatic CRC. In our previous aCGH study,
Introduction
Colorectal cancer (CRC) is the third most common cancer and the second cause of cancer-related death in the Western world [ 1 ] . The prognosis of CRC depends on tumor stage and treatment. For more than 50 years 5-fluorouracil (5-FU)-based therapy has remained the treatment of choice in both the adjuvant and palliative setting of CRC therapy. Currently, 5-FU or its prodrug capecitabine are given as combined therapeutic regimens including oxaliplatin, leucovorin, irinotecan, cetuximab and bevacizumab, which increased responses in first-line therapy up to 40% [ 2 ] . However, the overall prognosis is still poor, and no markers can reliably predict the subset of patients who will respond to cytotoxic drugs [ 3 ] . Therefore, the main challenges in CRC chemotherapy rely both on the development of new combinations and on the identification of markers to predict drug sensitivity.
The leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) is the most common chemotherapeutic regimen used for first-line treatment of metastatic CRC. In this regimen, cytotoxicity is achieved through thymidylate synthase (TS) inhibition by 5-FU, which leads to disturbance on DNA replication and repair, and through topoisomerase I inhibition by irinotecan, which leads to double-strand breaks. The efficacy of this regimen as well as capecitabine plus irinotecan suggested that other TS inhibitors might synergize with irinotecan, and Phase I/II studies for second-line treatment of CRC showed promising results of combinations with the multitargeted antifolate pemetrexed, which exerts its effects primarily through TS inhibition [ 4 , 5 ] . However, a randomized 
Figure 1
Scheme showing proteins involved in Pemetrexed and 5FU activity. All the enzymes encoded by the candidate genes/polymorphisms assessed in this study are marked in red. Pemetrexed is transported into the cells through SLC19A1 and is metabolized by FPGS to its active metabolite. Pemetrexed polyglutamate forms inhibit TS, DHFR, GARFT, ATIC and MTHFD1L, fundamental for the de novo biosynthesis of thymidine and purine nucleotides. See for further explanation the text.
Phase II trial of pemetrexed + irinotecan (ALIRI) showed similar efficacy and safety, but significantly shorter progression-free survival (PFS) compared with FOLFIRI treatment [ 4 , 6 ] . These results prompted further molecular studies on key determinants of activity for different TS inhibitors ( Figure 1 ). In particular, pemetrexed is an antifolate agent that acts by disturbing critical folate-dependent metabolic processes. Folates are required for the synthesis of thymidine and purines and also to generate methionine, which plays an important role in protein synthesis, polyamine synthesis and transmethylation, essential for cell proliferation [ 7 ] .
Several proteins can affect pemetrexed activity ( Figure 1 ). This drug is transported into the cells mainly through the reduced folate carrier (SLC19A1) system and the proton coupled folate transporter (PCFT). It is extensively meta bolized by folylpolyglutamate synthetase to more active metabolites. In vitro studies have shown that pemetrexed polyglutamation dramatically increases its affinity to TS, dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), and in a lesser extent to aminoimidazole carboxamide ribonucleotide formyltransferase (ATIC) and methylenetetrahydrofolate dehydrogenase (NADP + -dependent) 1-like (MTHFD1L), thus inhibiting their enzymatic activity [ 8 -10 ] . All these folate-dependent enzymes are fundamental for de novo biosynthesis of thymidine and purine nucleotides. TS catalyzes the methylation of deoxyuridylate (dUMP) to deoxythymidylate (dTMP) using 5,10-methylenetetrahydrofolate (methylene-THF) as a cofactor. This function maintains the dTMP (thymidine-5 ′ monophosphate) pool critical for DNA replication and repair. DHFR converts dihydrofolate into tetrahydrofolate (THF), a methyl group shuttle required for de novo synthesis of purines, dTMP and certain amino acids. The protein encoded by GARFT is a trifunctional polypeptide, which has phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase and phosphoribosylaminoimidazole synthetase activity that are also required for de novo purine biosynthesis. The ATIC gene encodes a bifunctional protein that catalyzes the last two steps of the de novo purine biosynthetic pathway. The N-terminal domain has phosphoribosylaminoimidazolecarboxamide formyltransferase activity, and the C-terminal domain has IMP cyclohydrolase activity. MTHFD1L is an enzyme involved in THF synthesis in mitochondria. One-carbon substituted forms of THF are involved in de novo synthesis of purines and thymidylate, as well as in cellular methylation reactions through the regeneration of methionine from homocysteine [ 11 ] .
The identification of genetic variables that predict resistance, sensitivity or toxicity to chemotherapy is of major interest in order to determine which patients would benefit most from standard therapy in terms of safety and efficacy. Moreover, although pemetrexed is not used for the treatment of CRC, the analysis from patients treated with ALIRI is an important step for the development of clinical pharmacogenetic models to understand genetic variations influencing the impact of this TS inhibitor that might apply to other tumor types.
Gene polymorphisms of TSER, MTHFR-677C [ 12 -21 ] . Nevertheless, few data were published relating these polymorphisms to treatment outcome in patients with CRC treated with 5-FU or pemetrexed. Similarly, although so far no data have been published relating treatment outcome to SLC-19A180G > A and AMPD-134C > T polymorphisms, these two polymorphisms also play an important role in pemetrexed transport and purine nucleotide cycle and might influence clinical outcome.
Therefore, the main aim of this study was to identify a possible relation between these polymorphisms and PFS in patients with locally advanced or metastatic CRC treated with pemetrexed and/or 5-FU based therapy. The secondary aims were to identify a possible relation of these polymorphisms with treatment toxicity or clinical response.
Materials and methods

Patients
This multicenter pharmacogenetic study involved a number of patients enrolled from February 2004 to September 2005 in Australia, Germany, Greece, The Netherlands, Spain and Russia [ 6 ] . The clinical outcome of this study (JMAZ) has been published separately [ 6 ] . Patients ≥ 18 years of age with histologically or cytologically confi rmed adenocarcinoma of the colon or rectum with locally advanced or metastatic disease were enrolled. Eligible patients had at least one unidimensional measurable lesion defi ned by response evaluation criteria in solid tumors (RECIST) [ 22 ] , a life expectancy ≥ 12 weeks, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 -2, and adequate marrow reserve, hepatic and renal function. No previous chemotherapy for advanced disease was allowed. Prior adjuvant therapy (except irinotecan) was allowed if given ≥ 12 months before enrolment. All patients provided written informed consent. The study was performed according to the Declaration of Helsinki, and the protocol was reviewed and approved by the appropriate ethical review board. 
Study design and treatment
Baseline and treatment assessment
Pretreatment evaluation included a complete medical examination, ECOG PS, baseline tumor measurement via magnetic resonance imaging and clinical laboratory tests. Tumor measurements were repeated before every other cycle for patients receiving ALIRI and before every cycle for patients receiving FOLFIRI. Body surface area calculations, body weight, clinical laboratory tests and toxicity assessments according to the National Cancer Institute (NCI) Common Toxicity Criteria, version 2.0, were completed before each cycle.
Candidate polymorphisms
Candidate genes/polymorphisms were selected via a functional approach in order to evaluate determinants known to modulate drug metabolism and mechanism of action ( Figure 1 , Table 1 ). Therefore, we used the following criteria: (i) that the gene was part of a pathway for which there is a credible scientifi c basis to support its involvement in the study of drug activity; (ii) that the gene had an established, well-documented genetic polymorphism; (iii) that the frequency of the polymorphism was high enough that its eff ect on clinical outcome would be meaningful; and (iv) that the polymorphism had some degree of likelihood to alter the function of the gene in a biologically relevant manner. The SLC1-19A180G > A polymorphism might aff ect pemetrexed transport into malignant cells [ 23 ] , whereas TSER genotypes might be associated with tumoral TS level; nevertheless, their value as a predictor of response to treatment with 5-FU is still controversial [ 20 , 24 , 25 ] . The ATIC-347C > G polymorphism might play an important role in sensitivity to the drug and in purine biosynthesis [ 26 ] , whereas the MTHFR-677C > T and 1298A > C polymorphisms might aff ect folate distribution either to DNA synthesis or to homocysteine remethylation [ 27 ] . Furthermore, the MTHFD1-1958G > A polymorphism might aff ect MTHFD expression which is involved in folate and methionine meta bolism [ 7 ] , whereas the MTR-2756A > G and MTRR-66A > G polymorphisms might aff ect the expression of MTR and MTRR , respectively, which are critical in methionine synthesis [ 28 ] . Finally, the SHMT1-1420C > T polymorphism might aff ect SHMT expression, which plays a pivotal role in the reversible conversion of serine and THF to glycine and methylene-THF [ 28 ] , whereas AMPD catalyzes the irreversible deamination of adenosine monophosphate to inosine monophosphate [ 29 ] and plays a role in the purine nucleotide cycle.
Genotyping
DNA was isolated from pretreated blood samples using the QIAamp DNA mini kit (Qiagen, Venlo, the Netherlands) according to the man- ufacturer ' s instructions, and DNA yields and integrity were checked at 260 -280 nm with the NanoDrop ® -1000-Detector (NanoDrop Technologies, Wilmington, DE, USA). TSER and MTHFR-677C > T polymorphisms were examined by the Laboratory of Medical Oncology (VU University Medical Center, Amsterdam, The Netherlands), whereas
polymorphisms were assessed by the Laboratory of Clinical Chemistry (Erasmus MC, Rotterdam, The Netherlands).
The TSER genotype was assessed by polymerase chain reaction (PCR) amplifi cation of the enhancer region (5 ′ UTR) of the TS gene using a forward primer (5 ′ -GTG GCT CCT GCG TTT CCC CC -3 ′ ) and a reverse primer (5 ′ -GCT CCG AGC CGG CCA CAG GCA TGG CGC GG -3 ′ ) as described previously [ 14 , 24 ] .
All other polymorphisms were evaluated with Taqman ® probes based assays using the ABI PRISM-7000 Sequence Detection System instrument equipped with SDS version 1.3.0 soft ware (Applied Biosystems, Leusden, the Netherlands). These PCR reactions were performed using 1.2 μ L DNA sample and 5 μ L reagents, in a total reaction volume of 6.2 μ L. The reaction mixture underwent the following thermocycling conditions: 95 ° C for 10 min, 40 amplifi cation cycles at 92 ° C for 15 s followed by a fi nal annealing and extension step at 60 ° C for 1 min. Details of the genetic variants, primers and probes are in Supplemental Table 1 .
Statistical analysis
The primary endpoint was to investigate the association between pharmacogenetic data and PFS, whereas the secondary endpoints included the association between polymorphisms and clinical response, clinical benefi t and treatment toxicity. All analyses of the samples were done in a blinded manner relative to clinical outcome. Genotype frequencies were checked for agreement with those expected under the Hardy-Weinberg equilibrium with the webbased SNP analyzer soft ware ( http://snp.istech21.com/snpanalyzer/2.0/ ). PFS was defi ned as the time from study enrolment to disease progression or death from any cause, as appropriate. As this study was not designed to estimate overall survival (OS), no follow-up was performed on patients aft er relapse and second-line therapy. The Kaplan-Meier method was used to plot PFS, and the log-rank test to compare curves.
Objective response was evaluated according to RECIST criteria. Toxicity was assessed by the NCI Common Toxicity Criteria, version 2.0.
Demographic and clinical information were compared by treatment group, using Pearson ' s χ 2 two-sided test. This test was also used to compare clinical information (assessed as PFS, clinical response and toxicity) across genotype. The univariate analysis included different baseline demographic and clinical characteristics, such as gender, age, PS and clinical stage. Statistical analyses were performed grouping patients according to three diff erent genotypes for each polymorphism. Further analyses were performed: (i) collapsing the homozygous and heterozygous genotypes (for all the population) when they had the same direction of eff ect (e.g., both had reduced/ increased PFS compared with the reference group) and (ii) combining variant alleles associated with worse outcome (risk genotype). The signifi cant prognostic variables in the univariate analysis were included in multivariate analyses, using Cox ' s proportional hazards model.
Data were analyzed using SPSS-16 soft ware (SPSS, Inc., Chicago, IL, USA). All analyses were two-sided and a p-value < 0.05 was considered statistically signifi cant.
As this is an exploratory study, no correction for multiple testing was performed.
Results
Genotyping analyses were performed in 84 patients. Patient age ranged from 33 to 78 years. Five of these patients had no metastatic disease, whereas ECOG PS was rated 0 for 25, 1 for 52, and 2 for 7 patients, respectively. Forty patients underwent treatment with the FOLFIRI regimen, and 44 were treated the ALIRI regimen. No significant difference in any clinical feature was observed between patients treated with these regimens, and no significant difference was observed between each regimen and PFS ( Figure 2 A) .
Polymorphisms and outcome
Genotyping was successfully performed in the vast majority of DNA samples. All polymorphisms except TSER (p = 0.04) followed the Hardy-Weinberg equilibrium. As this analysis was performed in individuals from different geographic areas (e.g., 64% from Australia and Russia), population substructure is the most likely explanation for this deviation. However, the allelic frequencies of all the studied polymorphisms are consistent with those observed in previous reports and in the NCBI and NCI-SNP500 databases ( Table 1 ) . At univariate analysis, polymorphisms of MTR-2756A > G, SHMT1-1420C > T and ATIC-347C > G were significantly associated with PFS ( ( Table 3 ) .
Because MTR, SHMT1 and ATIC are all involved in folate pathways, we further explored the effect of a combination of their risk genotypes on PFS. The deleterious genotypes included MTR-2756A > G GG, SHMT1-1420C > T CC and ATIC-347C > G GG , all of which were related to shorter PFS ( Figure 2B ). These combinations were analyzed in 81 patients, and patients carrying two risk genotypes had a significantly shorter PFS (3.9 months; 95% CI, 2.4 -5.4 months; p < 0.001). Patients with two risk genotypes were
However, no significant difference on PFS was observed between these two groups.
At univariate analysis by treatment group ( Table 2 ) , polymorphisms of TSER, MTHFR-1298A > C and ATIC-347C > G were associated with significantly differential PFS in the ALIRI group. In particular, the less common variant genotypes of MTHFR-1298A > C and ATIC-347C > G polymorphisms were associated with decreased PFS. However, the more common polymorphic variant of SHMT1-1420C > T and the less common variant of SLC19A180G > A were associated with significantly shorter PFS in the FOLFIRI group.
The analysis of the correlation with clinical response ( Table 4 ) The results of the correlation with toxicity are described in Table 5 , showing that the polymorphism MTHFR-677C > T was significantly associated with blood and bone marrow grade 3 -4 toxicity. In particular, the patients carrying the CC genotype experienced a significantly higher frequency of blood and bone marrow grade 3 -4 toxicities (50%) compared with MTHFR-677C > T TT + CT grouped genotypes (25.6%; p = 0.038).
Discussion
This study evaluated the impact of functional polymorphisms on clinical outcome in locally advanced or metastatic CRC patients treated with ALIRI and/or FOLFIRI, and to our knowledge, is the first study to suggest the role of MTR-2756A > G, SHMT1-1420C > T and ATIC-347C > G polymorphisms as possible predictive factors for PFS. It is also the first study to show the correlation of the SHMT1-1420C > T and ATIC-347C > G polymorphisms with PFS in patients treated with FOLFIRI and ALIRI regimens, respectively. Of note, in patients evaluated for polymorphism analysis no significant difference of median PFS was observed between the two regimens. Probably due to smaller sample size, this result was different from that obtained by Underhill et al. [ 6 ] where a significant longer PFS was observed on patients submitted to the FOLFIRI regimen. However, the lack of significant differences between PFS allowed us to perform all assessments on the pooled data, except for the analysis of polymorphisms on PFS by specific treatment group.
The most important results observed in this study include: (i) the shorter PFS for MTR-2756A > G GG, SHMT-1420C > T CC and ATIC-347C > G GG polymorphisms, at univariate analysis; (ii) the significant impact of MTR-2756A > G AA + AG, SHMT1-1420C > T TT + CT and ATIC-347C > G CC + CG polymorphisms on risk of progression, as observed at multivariate analysis; and (iii) the strong combined effect on PFS for MTR-2756A > G, SHMT1-1420C > T and ATIC-347C > G polymorphisms when combined risk genotypes were analyzed. These results are in accordance with the fact that all mentioned genes have a significant role in the folate pathways and consequent DNA synthesis.
The SHMT1-1420C > T polymorphic variant " T " produces a modified protein (L474F) that, although not affecting catalytic activity, impairs SHMT1 nuclear transport and, subsequently, TS activity. This modified protein accumulates in the cytoplasm where it inhibits cellular methylation reactions by sequestering 5-methyl-THF [ 30 ] . 5-Methyl-THF is required to convert homocysteine into methionine, which is needed for the synthesis of S-adenosylmethionine (SAM). SAM plays an important role in intracellular methylation reactions, including DNA methylation, which is one of the critical molecular mechanisms for DNA stability [ 31 ] . Furthermore, the lack of 5-methyl-THF due to sequestration by L474F leads to an increase of homocysteine concentrations which has been related to increased DNA damage [ 32 ] . All these mechanisms can explain why homozygous TT carriers might be more sensitive to cytotoxic activity of TS inhibitors and antifolates, resulting in significantly longer PFS.
To date, no association was found between ATIC polymorphisms and the effect of pemetrexed in cancer. However, a correlation with the activity of MTX was hypothesized by Weisman et al., suggesting that ATIC-347C > G GG encoded for a protein causing decreased de novo purine synthesis [ 33 ] . The results obtained in the present study are in accordance with previous studies in rheumatoid arthritis and psoriasis, showing that the " C " allele was associated with lower disease activity [ 16 , 34 , 35 ] .
When the impact of polymorphisms on PFS was assessed by treatment group, TSER-3R, MTHFR-1298A > C AA and ATIC-347C > G CC + CG polymorphisms were significantly associated with longer PFS in patients treated with ALIRI. Several studies reported controversial data about [ 24 , 36 -44 ] , whereas recent studies did not find a correlation of this polymorphism with outcome after pemetrexed-based therapies in mesothelioma and non-small cell lung cancer (NSCLC) [ 12 , 36 ] . To our knowledge, there are no data on MTHFR-1298A > C polymorphisms on CRC patients treated with pemetrexed; nevertheless, the present results are in accordance with data on advanced gastric cancer patients treated with pemetrexed, showing a favorable prognostic role of the wild-type genotype [ 45 ] . These data are also similar to the results of the clinical/pharmacogenetic study by Smit and colleagues in NSCLC patients treated with pemetrexed. In this study, homozygous mutation for MTHFR-1298A > C was shown to have a trend towards a significant association with shorter PFS when compared with wild-type or heterozygous mutations [ 12 ] . The longer PFS observed in MTHFR-1298A > C AA carriers might be explained by the role of MTHFR on methylene-THF conversion to 5-methyl-THF. The MTHFR-1298A > C polymorphism is within the regulatory region of MTHFR and is known to reduce enzyme activity leading to a decreased pool of 5-methyl-THF, which leads in turn to an increase of homocysteine concentrations that have been related to increased DNA damage [ 32 , 46 ] .
In the FOLFIRI group, SHMT1-1420C > T and SLC-19A180G > A polymorphisms have shown a significant association with differential PFS. Once again, the significantly longer PFS observed in SHMT1-1420C > T TT carriers might be explained by the increase of homocysteine concentration which has been related to increased DNA damage [ 32 ] . Surprisingly, the SLC-19A1180G > A GG + GA polymorphism showed a significant association with shorter PFS in patients treated with FOLFIRI, but not in the ALIRI group. A previous study suggested that 5-FU transport may be mediated by SLC22A7 [ 47 ] , while it is well established that antifolates such as methotrexate and pemetrexed are actively transported into cells by SLC-19A1 [ 23 , 47 ] . Furthermore, SLC-19A1 -IVS4(2117)C > T, IVS5(9148) C > A and exon6(2522)C > T polymorphisms were recently correlated to survival after pemetrexed-based therapy [ 48 ] . Nevertheless, there are no data correlating SLC-19A180G > A polymorphism to pemetrexed survival or PFS [ 48 ] . A possible explanation for the significant association found in our dataset is that leucovorin, used to enhance 5-FU activity, is also transported into the cell by SLC-19A1. The protein codified by the SLC-19A180G > A AA polymorphic gene might have higher transport activity leading to an increased concentration of intracellular leucovorin resulting in an increase in 5-FU activity. Furthermore, the effect of both MTHFR and SLC-19A1 polymorphisms on PFS might be mediated by the influence on total homocysteine levels [ 49 ] , which have a crucial impact on DNA damage.
To our knowledge, this is also the first study reporting a significant correlation of MTHFD-1958G > A polymorphisms with clinical response. To date, the 1958G > A transition of MTHFD1 has been linked with genetic higher risk of having a child with neural tube defects ( " AA " carriers) [ 50 ] or schizophrenia ( " AA " or " AG " carriers) [ 51 ] . Its association with response to cytotoxic drugs may result from the effect on de novo biosynthesis of N 5 -methyltetrahydrofolate and subsequent reduction of SAM concentration, favoring DNA damage.
The identification of genetic variables that predict toxicity to chemotherapy is of major interest in patient selection avoiding the use of harmful therapies, and in the present study specific polymorphisms of MTHFR were identified as significant predictors for appearance of grade 3 -4 blood and bone marrow toxicity. In particular, carriers of the MTHFR-677C > T TT + CT genotypes had a significantly lower risk to experience this severe toxicity compared with patients harboring the MTHFR-677C > T CC genotype. These results are in accordance with data from a clinical investigation on advanced gastric cancer patients treated with 5-fluoropyrimidine-based chemotherapy, which reported a significant association between the TT genotype with higher treatment-related general toxicity [ 52 ] . Conversely, other studies showed that the CC genotype was associated with grade 3 -4 infections and diarrhea [ 52 , 53 ] . However, a few studies analyzed the role of the MTHFR-677C > T polymorphism on toxic side effects after fluoropyrimidinebased therapy in CRC, drawing inconclusive results, while no data are available on the possible correlation with pemetrexed toxicity [ 54 ] , and thus further studies are warranted.
In conclusion, although the present exploratory study was limited by sample size, and no correction for multiple testing was performed, the data on the correlation of polymorphisms in genes involved in the folate pathway or in antifolate chemotherapy with clinical outcome underscore the importance of a candidate gene and pathwaybased approach in a genotyping investigation. These analyses should be integrated with genome-wide analysis, as described in our previous study [ 55 ] .
Ultimately, the validation of the role of these polymorphisms in prospective multicenter trials might offer new tools for treatment optimization of both currently available regimens in selected CRC patients (e.g., FOLFIRI) and of pemetrexed-based treatment in other tumor types.
